Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2014

Open Access 01-12-2014 | Original investigation

Leptin is associated with vascular endothelial function in overweight patients with type 2 diabetes

Authors: Tomoaki Morioka, Masanori Emoto, Yuko Yamazaki, Naoya Kawano, Satoshi Imamura, Ryutaro Numaguchi, Hiromi Urata, Koka Motoyama, Katsuhito Mori, Shinya Fukumoto, Hidenori Koyama, Tetsuo Shoji, Masaaki Inaba

Published in: Cardiovascular Diabetology | Issue 1/2014

Login to get access

Abstract

Background

The adipocyte-derived hormone leptin plays a key role in the regulation of appetite and body weight. Recent studies have suggested that leptin is also involved in the pathogenesis of obesity-related atherosclerosis and cardiovascular disease. In this study, we investigated the association of plasma leptin levels with vascular endothelial function in lean and overweight patients with type 2 diabetes.

Methods

One hundred seventy-one type 2 diabetic patients, of which 85 were overweight (body mass index (BMI) ≥ 25 kg/m2), were enrolled in this cross-sectional study. Plasma leptin concentrations were measured by enzyme-linked immunosorbent assay. Flow-mediated dilatation (FMD) of the brachial artery was measured to evaluate vascular endothelial function using ultrasound.

Results

No significant difference in FMD was found between the lean and overweight groups (7.0 ± 3.8% and 6.5 ± 3.6%, respectively; p = 0.354). FMD was negatively correlated with age (r = −0.371, p < 0.001) and serum creatinine levels (r = −0.236, p = 0.030), but positively correlated with BMI (r = 0.330, p = 0.002) and plasma leptin levels (r = 0.290, p = 0.007) in the overweight group. FMD was not associated with any parameters in the lean group. Multiple regression analysis including possible atherosclerotic risk factors revealed that the plasma leptin level (β = 0.427, p = 0.013) was independently associated with FMD in the overweight group (R 2 = 0.310, p = 0.025), but not the lean group.

Conclusion

Plasma leptin levels are associated with vascular endothelial function in overweight patients with type 2 diabetes.
Appendix
Available only for authorised users
Literature
1.
Beltowski J: Leptin and atherosclerosis. Atherosclerosis. 2006, 189 (1): 47-60. 10.1016/j.atherosclerosis.2006.03.003.CrossRefPubMed
2.
Guzik TJ, Mangalat D, Korbut R: Adipocytokines - novel link between inflammation and vascular function?. J Physiol Pharmacol. 2006, 57 (4): 505-528.PubMed
3.
4.
5.
Soderberg S, Ahren B, Jansson JH, Johnson O, Hallmans G, Asplund K, Olsson T: Leptin is associated with increased risk of myocardial infarction. J Intern Med. 1999, 246 (4): 409-418. 10.1046/j.1365-2796.1999.00571.x.CrossRefPubMed
6.
Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N: Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 2001, 104 (25): 3052-3056. 10.1161/hc5001.101061.CrossRefPubMed
7.
Tomiyama H, Yamashina A: Non-invasive vascular function tests: their pathophysiological background and clinical application. Circ J. 2010, 74 (1): 24-33. 10.1253/circj.CJ-09-0534.CrossRefPubMed
8.
Kimura K, Tsuda K, Baba A, Kawabe T, Boh-oka S, Ibata M, Moriwaki C, Hano T, Nishio I: Involvement of nitric oxide in endothelium-dependent arterial relaxation by leptin. Biochem Biophys Res Commun. 2000, 273 (2): 745-749. 10.1006/bbrc.2000.3005.CrossRefPubMed
9.
Lembo G, Vecchione C, Fratta L, Marino G, Trimarco V, D'Amati G, Trimarco B: Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes. 2000, 49 (2): 293-297. 10.2337/diabetes.49.2.293.CrossRefPubMed
10.
Nakagawa K, Higashi Y, Sasaki S, Oshima T, Matsuura H, Chayama K: Leptin causes vasodilation in humans. Hypertens Res. 2002, 25 (2): 161-165. 10.1291/hypres.25.161.CrossRefPubMed
11.
Matsuda K, Teragawa H, Fukuda Y, Nakagawa K, Higashi Y, Chayama K: Leptin causes nitric-oxide independent coronary artery vasodilation in humans. Hypertens Res. 2003, 26 (2): 147-152. 10.1291/hypres.26.147.CrossRefPubMed
12.
Beltowski J, Wojcicka G, Jamroz-Wisniewska A, Marciniak A: Resistance to acute NO-mimetic and EDHF-mimetic effects of leptin in the metabolic syndrome. Life Sci. 2009, 85 (15–16): 557-567.CrossRefPubMed
13.
Korda M, Kubant R, Patton S, Malinski T: Leptin-induced endothelial dysfunction in obesity. Am J Physiol Heart Circ Physiol. 2008, 295 (4): H1514-1521. 10.1152/ajpheart.00479.2008.PubMedCentralCrossRefPubMed
14.
Knudson JD, Dincer UD, Zhang C, Swafford AN, Koshida R, Picchi A, Focardi M, Dick GM, Tune JD: Leptin receptors are expressed in coronary arteries, and hyperleptinemia causes significant coronary endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2005, 289 (1): H48-56. 10.1152/ajpheart.01159.2004.CrossRefPubMed
15.
Sundell J, Huupponen R, Raitakari OT, Nuutila P, Knuuti J: High serum leptin is associated with attenuated coronary vasoreactivity. Obes Res. 2003, 11 (6): 776-782. 10.1038/oby.2003.108.CrossRefPubMed
16.
Gonzalez M, Lind L, Soderberg S: Leptin and endothelial function in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Atherosclerosis. 2013, 228 (2): 485-490. 10.1016/j.atherosclerosis.2013.03.018.CrossRefPubMed
17.
Cosentino F, Luscher TF: Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol. 1998, 32 (Suppl 3): S54-61.PubMed
18.
American Diabetes Association: Standards of medical care in diabetes--2013. Diabetes Care. 2013, 1 (36 Suppl 1): 11-66.CrossRef
19.
Yamazaki Y, Emoto M, Morioka T, Kawano N, Lee E, Urata H, Tsuchikura S, Motoyama K, Mori K, Fukumoto S, et al: Clinical impact of the leptin to soluble leptin receptor ratio on subclinical carotid atherosclerosis in patients with type 2 diabetes. J Atheroscler Thromb. 2013, 20 (2): 186-194. 10.5551/jat.14662.CrossRefPubMed
20.
Golledge J, Clancy P, Jamrozik K, Norman PE: Obesity, adipokines, and abdominal aortic aneurysm: health in men study. Circulation. 2007, 116 (20): 2275-2279. 10.1161/CIRCULATIONAHA.107.717926.CrossRefPubMed
21.
Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D,et al: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International brachial arteryreactivity task force. J Am Coll Cardiol. 2002, 39 (2): 257-265. 10.1016/S0735-1097(01)01746-6.CrossRefPubMed
22.
Inoue T, Matsuoka H, Higashi Y, Ueda S, Sata M, Shimada KE, Ishibashi Y, Node K: Flow-mediated vasodilation as a diagnostic modality for vascular failure. Hypertens Res. 2008, 31 (12): 2105-2113. 10.1291/hypres.31.2105.CrossRefPubMed
23.
Kawano N, Emoto M, Mori K, Yamazaki Y, Urata H, Tsuchikura S, Motoyama K, Morioka T, Fukumoto S, Shoji T, et al: Association of endothelial and vascular smooth muscle dysfunction with cardiovascular risk factors, vascular complications, and subclinical carotid atherosclerosis in type 2 diabetic patients. J Atheroscler Thromb. 2012, 19 (3): 276-284. 10.5551/jat.10629.CrossRefPubMed
24.
Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, Kajikawa M, Matsumoto T, Hidaka T, Kihara Y, et al: Nitroglycerine-induced vasodilation for assessment of vascular function: a comparison with flow-mediated vasodilation. Arterioscler Thromb Vasc Biol. 2013, 33 (6): 1401-1408. 10.1161/ATVBAHA.112.300934.CrossRefPubMed
25.
Tomiyama H, Higashi Y, Takase B, Node K, Sata M, Inoue T, Ishibashi Y, Ueda S, Shimada K, Yamashina A: Relationships among hyperuricemia, metabolic syndrome, and endothelial function. Am J Hypertens. 2011, 24 (7): 770-774. 10.1038/ajh.2011.55.CrossRefPubMed
26.
Adams MR, Robinson J, McCredie R, Seale JP, Sorensen KE, Deanfield JE, Celermajer DS: Smooth muscle dysfunction occurs independently of impaired endothelium-dependent dilation in adults at risk of atherosclerosis. J Am Coll Cardiol. 1998, 32 (1): 123-127. 10.1016/S0735-1097(98)00206-X.CrossRefPubMed
27.
Koh KK, Han SH, Oh PC, Shin EK, Quon MJ: Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction. Atherosclerosis. 2010, 209 (2): 307-313. 10.1016/j.atherosclerosis.2009.09.007.PubMedCentralCrossRefPubMed
28.
Tomiyama H, Matsumoto C, Yamada J, Teramoto T, Abe K, Ohta H, Kiso Y, Kawauchi T, Yamashina A: The relationships of cardiovascular disease risk factors to flow-mediated dilatation in Japanese subjects free of cardiovascular disease. Hypertens Res. 2008, 31 (11): 2019-2025. 10.1291/hypres.31.2019.CrossRefPubMed
29.
Vlachopoulos C, Manesis E, Baou K, Papatheodoridis G, Koskinas J, Tiniakos D, Aznaouridis K, Archimandritis A, Stefanadis C: Increased arterial stiffness and impaired endothelial function in nonalcoholic Fatty liver disease: a pilot study. Am J Hypertens. 2010, 23 (11): 1183-1189. 10.1038/ajh.2010.144.CrossRefPubMed
30.
Mancini F, Cianciosi A, Reggiani GM, Facchinetti F, Battaglia C, de Aloysio D: Endothelial function and its relationship to leptin, homocysteine, and insulin resistance in lean and overweight eumenorrheic women and PCOS patients: a pilot study. Fertil Steril. 2009, 91 (6): 2537-2544. 10.1016/j.fertnstert.2008.03.023.CrossRefPubMed
31.
Narita K, Murata T, Hamada T, Kosaka H, Sudo S, Mizukami K, Yoshida H, Wada Y: Associations between trait anxiety, insulin resistance, and atherosclerosis in the elderly: a pilot cross-sectional study. Psychoneuroendocrinology. 2008, 33 (3): 305-312. 10.1016/j.psyneuen.2007.11.013.CrossRefPubMed
32.
Golledge J, Leicht AS, Crowther RG, Glanville S, Clancy P, Sangla KS, Spinks WL, Quigley F: Determinants of endothelial function in a cohort of patients with peripheral artery disease. Cardiology. 2008, 111 (1): 51-56. 10.1159/000113428.CrossRefPubMed
33.
Gupta AK, Johnson WD, Johannsen D, Ravussin E: Cardiovascular risk escalation with caloric excess: a prospective demonstration of the mechanics in healthy adults. Cardiovasc Diabetol. 2013, 12: 23-10.1186/1475-2840-12-23.PubMedCentralCrossRefPubMed
34.
Melikian N, Wheatcroft SB, Ogah OS, Murphy C, Chowienczyk PJ, Wierzbicki AS, Sanders TA, Jiang B, Duncan ER, Shah AM, et al: Asymmetric dimethylarginine and reduced nitric oxide bioavailability in young Black African men. Hypertension. 2007, 49 (4): 873-877. 10.1161/01.HYP.0000258405.25330.80.CrossRefPubMed
35.
Oflaz H, Ozbey N, Mantar F, Genchellac H, Mercanoglu F, Sencer E, Molvalilar S, Orhan Y: Determination of endothelial function and early atherosclerotic changes in healthy obese women. Diabetes Nutr Metab. 2003, 16 (3): 176-181.PubMed
36.
Saarikoski LA, Huupponen RK, Viikari JS, Marniemi J, Juonala M, Kahonen M, Raitakari OT: Adiponectin is related with carotid artery intima-media thickness and brachial flow-mediated dilatation in young adults–the cardiovascular risk in young Finns study. Ann Med. 2010, 42 (8): 603-611. 10.3109/07853890.2010.514284.CrossRefPubMed
37.
Singhal A, Farooqi IS, Cole TJ, O'Rahilly S, Fewtrell M, Kattenhorn M, Lucas A, Deanfield J: Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease?. Circulation. 2002, 106 (15): 1919-1924. 10.1161/01.CIR.0000033219.24717.52.CrossRefPubMed
38.
Varady KA, Bhutani S, Klempel MC, Phillips SA: Improvements in vascular health by a low-fat diet, but not a high-fat diet, are mediated by changes in adipocyte biology. Nutr J. 2011, 10: 8-10.1186/1475-2891-10-8.PubMedCentralCrossRefPubMed
39.
Mohler ER, Sibley AA, Stein R, Davila-Roman V, Wyatt H, Badellino K, Rader DJ, Klein S, Foster GD: Endothelial function and weight loss: comparison of low-carbohydrate and low-fat diets. Obesity (Silver Spring). 2013, 21 (3): 504-509. 10.1002/oby.20055.CrossRef
40.
Klempel MC, Kroeger CM, Norkeviciute E, Goslawski M, Phillips SA, Varady KA: Benefit of a low-fat over high-fat diet on vascular health during alternate day fasting. Nutr Diabetes. 2013, 3: e71-10.1038/nutd.2013.14.PubMedCentralCrossRefPubMed
41.
Mavri A, Poredos P, Suran D, Gaborit B, Juhan-Vague I: Effect of diet-induced weight loss on endothelial dysfunction: early improvement after the first week of dieting. Heart Vessels. 2011, 26 (1): 31-38. 10.1007/s00380-010-0016-1.CrossRefPubMed
42.
Fruhbeck G: Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes. 1999, 48 (4): 903-908. 10.2337/diabetes.48.4.903.CrossRefPubMed
43.
Benkhoff S, Loot AE, Pierson I, Sturza A, Kohlstedt K, Fleming I, Shimokawa H, Grisk O, Brandes RP, Schroder K: Leptin potentiates endothelium-dependent relaxation by inducing endothelial expression of neuronal NO synthase. Arterioscler Thromb Vasc Biol. 2012, 32 (7): 1605-1612. 10.1161/ATVBAHA.112.251140.CrossRefPubMed
44.
Momin AU, Melikian N, Shah AM, Grieve DJ, Wheatcroft SB, John L, El Gamel A, Desai JB, Nelson T, Driver C, et al: Leptin is an endothelial-independent vasodilator in humans with coronary artery disease: evidence for tissue specificity of leptin resistance. Eur Heart J. 2006, 27 (19): 2294-2299. 10.1093/eurheartj/ehi831.CrossRefPubMed
45.
Brook RD, Bard RL, Bodary PF, Eitzman DT, Rajagopalan S, Sun Y, Depaoli AM: Blood pressure and vascular effects of leptin in humans. Metab Syndr Relat Disord. 2007, 5 (3): 270-274. 10.1089/met.2006.0023.CrossRefPubMed
46.
Jung CH, Kim BY, Kim CH, Kang SK, Jung SH, Mok JO: Association of serum adipocytokine levels with cardiac autonomic neuropathy in type 2 diabetic patients. Cardiovasc Diabetol. 2012, 11: 24-10.1186/1475-2840-11-24.PubMedCentralCrossRefPubMed
47.
Beltowski J: Leptin and the regulation of endothelial function in physiological and pathological conditions. Clin Exp Pharmacol Physiol. 2012, 39 (2): 168-178. 10.1111/j.1440-1681.2011.05623.x.CrossRefPubMed
48.
Chiu FH, Chuang CH, Li WC, Weng YM, Fann WC, Lo HY, Sun C, Wang SH: The association of leptin and C-reactive protein with the cardiovascular risk factors and metabolic syndrome score in Taiwanese adults. Cardiovasc Diabetol. 2012, 11: 40-10.1186/1475-2840-11-40.PubMedCentralCrossRefPubMed
49.
Schinzari F, Tesauro M, Rovella V, Di Daniele N, Mores N, Veneziani A, Cardillo C: Leptin stimulates both endothelin-1 and nitric oxide activity in lean subjects but not in patients with obesity-related metabolic syndrome. J Clin Endocrinol Metab. 2013, 98 (3): 1235-1241. 10.1210/jc.2012-3424.CrossRefPubMed
50.
Martin SS, Qasim A, Reilly MP: Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol. 2008, 52 (15): 1201-1210. 10.1016/j.jacc.2008.05.060.PubMedCentralCrossRefPubMed
51.
Rodriguez A, Fortuno A, Gomez-Ambrosi J, Zalba G, Diez J, Fruhbeck G: The inhibitory effect of leptin on angiotensin II-induced vasoconstriction in vascular smooth muscle cells is mediated via a nitric oxide-dependent mechanism. Endocrinology. 2007, 148 (1): 324-331. 10.1210/en.2006-0940.CrossRefPubMed
52.
Quercioli A, Pataky Z, Montecucco F, Carballo S, Thomas A, Staub C, Di Marzo V, Vincenti G, Ambrosio G, Ratib O, et al: Coronary vasomotor control in obesity and morbid obesity: contrasting flow responses with endocannabinoids, leptin, and inflammation. JACC Cardiovasc Imaging. 2012, 5 (8): 805-815. 10.1016/j.jcmg.2012.01.020.CrossRefPubMed
Metadata
Title
Leptin is associated with vascular endothelial function in overweight patients with type 2 diabetes
Authors
Tomoaki Morioka
Masanori Emoto
Yuko Yamazaki
Naoya Kawano
Satoshi Imamura
Ryutaro Numaguchi
Hiromi Urata
Koka Motoyama
Katsuhito Mori
Shinya Fukumoto
Hidenori Koyama
Tetsuo Shoji
Masaaki Inaba
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2014
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-13-10

Other articles of this Issue 1/2014

Cardiovascular Diabetology 1/2014 Go to the issue

Original investigation

Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production

Original investigation

Younger age, higher body mass index and lower adiponectin concentration predict higher serum thromboxane B2 level in aspirin-treated patients with type 2 diabetes: an observational study

Original investigation

Earlier age at menarche is associated with higher diabetes risk and cardiometabolic disease risk factors in Brazilian adults: Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)

Original investigation

National trends in utilization and outcomes of coronary revascularization procedures among people with and without type 2 diabetes in Spain (2001–2011)

Original investigation

Microvascular dysfunction in the course of metabolic syndrome induced by high-fat diet

Original investigation

GLP-1 (7–36) amide restores myocardial insulin sensitivity and prevents the progression of heart failure in senescent beagles
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits